thermalife works, page-33

OK. So No.1 pharma, Pfizer, buys out No.39, King Pharmaceuticals, for USD$3.6b. I don't think we're comparing apples with apples here.

King had a turnover of USD$1.7b in 2009. http://en.wikipedia.org/wiki/King_Pharmaceuticals

Pfizer obviously can gain some efficiency by alleviating duplication. It may also have a roadmap that would have seen King as a major competitor, so they gobbled them up beforehand. Why try and beat them when you can make them join you? Saves everyone lots of bruising.

Seems like the market knew about Tripeptofen back in July 2004. http://www.theage.com.au/articles/2004/07/16/1089694560015.html?from=moreStories
6 years and we're still waiting? Too long for my liking. I might give it a miss. Good luck to all you holders.